{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:28:25Z","timestamp":1775064505553,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammatory markers are important prognostic factors in various cancers. This study investigated whether inflammatory markers of the Glasgow prognostic score (<jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content>) predicted progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) for patients with all cases of epithelial ovarian cancer (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>). Pretreatment <jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> was examined for the correlations with <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> in 216 patients in all stages of epithelial <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>. Statistical analyses were performed using the Mann\u2013Whitney <jats:italic>U<\/jats:italic>\u2010test. <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> were analyzed using the Kaplan\u2013Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. For all patients, the median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 35.1\u00a0months, and median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 46.7\u00a0months; follow\u2010up range was 1\u2013162\u00a0months. Kaplan\u2013Meier analysis revealed that patients with high <jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> 2) at pretreatment had a shorter <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> than did patients with lower <jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> 0\u00a0+\u00a01) in for early, advanced, and all\u2010stages of <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>:<jats:italic> P<\/jats:italic>\u00a0&lt;\u00a00.001 for early\u2010, advanced\u2010 and all\u2010stages; <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>;<jats:italic> P\u00a0<\/jats:italic>&lt;\u00a00.001 for early\u2010 and all\u2010stage, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.015 for advanced\u2010stage). <jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> 2) was also found to be an independent predictor of both recurrence (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002) and survival (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.001) of all cases of epithelial <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> by a multivariate analysis. <jats:styled-content style=\"fixed-case\">GPS<\/jats:styled-content> can serve as an indicator of poor prognosis in patients with all stages of epithelial <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>, including early\u2010stage disease and regardless of histology.<\/jats:p>","DOI":"10.1002\/cam4.681","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T12:44:19Z","timestamp":1456836259000},"page":"1074-1080","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer"],"prefix":"10.1002","volume":"5","author":[{"given":"Chiaki","family":"Omichi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Haraga","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Masuyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Cancer facts & figures 2009","author":"American Cancer Society","year":"2009"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2009.20.2.67"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0755-5"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-197211000-00001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(93)90129-7"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15327914nc392_8"},{"key":"e_1_2_6_8_1","first-page":"471","article-title":"C\u2010reactive protein and malignancy: clinico\u2010pathological association and therapeutic implication","volume":"32","author":"Wang C. S.","year":"2009","journal-title":"Chang. Gung. Med. J."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-011-1208-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601242"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601789"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602922"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602998"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000094562"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22400"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604027"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.11.011"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20376"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21652"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.03.058"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4726"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1044"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32832a7902"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2008.08.015"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.539"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.681","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.681","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:01:33Z","timestamp":1696615293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/cam4.681"],"URL":"https:\/\/doi.org\/10.1002\/cam4.681","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"2015-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}